Autobahn Therapeutics Announces Successful Financing To Support Strategic Advancement Of Abx-002 For Treatment Resistant Depression
Round Type
Funding Round
San DiegoBiotechnologyHealth CareTherapeuticsDescription
Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the closing of a $32.7 million financing to support the company’s continued commitment to transforming the treatment of CNS disorders, led by a strategic prioritization on addressing treatment-resistant depression (TRD). Current shareholders ARCH Venture Partners, Cowen Healthcare Investments, BVF Partners L.P., Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, Samsara BioCapital, Alexandria Venture Investments and GT Healthcare all participated in the round.
Quick answer
Autobahn Therapeutics raised an undisclosed amount in a Funding Round round, dated September 8, 2022. Autobahn Therapeutics is based in San Diego, California, United States.
- How much did Autobahn Therapeutics raise?
- Autobahn Therapeutics raised an undisclosed amount in a Funding Round round on September 8, 2022.
- What does Autobahn Therapeutics do?
- Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders.
- Where is Autobahn Therapeutics based and how big is it?
- Autobahn Therapeutics is based in San Diego, California, United States.
- Who are the decision-makers at Autobahn Therapeutics?
- Fundz holds 1 contact at Autobahn Therapeutics, including the Senior Director - Translational Neuroscience. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Autobahn Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Orionis Biosciences raised $55M (Funding Round) on October 19, 2022.
- Insmed Incorporated raised an undisclosed amount (Funding Round) on October 19, 2022.
- SURGE Therapeutics raised $26M (Series A) on October 17, 2022.
- Mablink Bioscience raised $30M (Series A) on October 14, 2022.
- CTRL Therapeutics raised $7.5M on October 12, 2022.
- Neumora raised $112M (Series B) on October 11, 2022.
Who to call at Autobahn Therapeutics, and when
A new round usually means Autobahn Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Autobahn Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Autobahn Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Autobahn Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Autobahn Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Autobahn Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.